Pete Frates, the Boston man who invented the Ice Bucket Challenge that raised millions for ALS, was reported to have kicked the bucket this summer — but it turned out to be a newspaper’s goof. The erroneous report stemmed from a headline in Britain’s Sun declaring that the 32-year-old had died…
Analysis of a large group of patients with amyotrophic lateral sclerosis (ALS) has shown that patients who also have dementia at diagnosis are more likely to have bulbar-onset ALS, a subtype of the disease in which patients first experience symptoms in the head and neck, including trouble speaking or swallowing. These patients also…
AB Science announced that abstracts reporting the use of Kinavet (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS) were selected for oral presentation at six international meetings in 2017. The abstracts include both preclinical and clinical data. The meetings include: XXIII World Congress of Neurology (WCN 2017) in Kyoto, Japan,…
Measuring changes in how humans find their way could enable earlier diagnosis of dementia in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) or Alzheimer’s disease, a new review study suggests. The research, “The Aging Navigational System,” appeared…
Amyotrophic lateral sclerosis (ALS) patients without any type of eye disease have thinner retinal layers, a new study shows. The research, titled “Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease” was published in the journal PLOS…
Routinely measuring neurofilaments in the blood and spinal fluid of people with amyotrophic lateral sclerosis (ALS) can help identify patients with early symptoms, concludes a recent study. Researchers led by Dr. Emily Feneberg of England’s University of Oxford presented the study, “Multicenter evaluation of neurofilaments in early symptom onset amyotrophic…
The company Verge Genomics, which uses genomic data for neuroscience therapeutics, announced that it will join specialized departments at four top universities to boost research in amyotrophic lateral sclerosis (ALS). The innovative industry-academic collaboration will combine machine learning with genomic, genetic, biological, and phenotypical data to accelerate the translation…
Research into the development of new therapies to treat several traumatic, inflammatory, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) received an important financial boost with the announcement by Disarm Therapeutics that it will receive $30 million in financing to develop treatments for axonal degeneration. Disarm was founded in 2016 as a…
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Revalesio’s investigational drug RNS60 to treat amyotrophic lateral sclerosis (ALS). The status gives incentives for companies to develop new therapies targeting rare and serious diseases, providing marketing exclusivity for…
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals, the drug developer, announced in a press release. Orphan drug status aims to encourage therapies for rare and serious diseases through incentives such as seven years of market…
